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Current approved drugs for Alzheimer’s disease (AD)
only treat symptoms of the disease and neither halt the pro-
gression nor provide sustainable improvement of the dis-
ease. The positive effects of these treatments on cognitive
functions and activities of daily living are at best modest
and transient and may have side effects [3,4]. Thus, there
is an important need for new medicines to either improve
cognition or reduce the progression of symptoms long
term in AD patients.
Pathologic hallmarks of AD are intracellular tau tangles
and deposition of extracellular amyloid plaques within the
brain [5,6]. The amyloid plaques are composed of variantsf of the Alzheimer’s Association. This is an open access article under the CC
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40/1–42 peptides and N- and C-terminally truncated Ab
peptides [7,8]. The truncated species Ab3–40/3–42 and
Ab11–40/11–42 bearing an N-terminal glutamate moiety
undergo posttranslational modification to their respective
oxo-prolyl (pyroglutamyl [pE])–containing amyloid-b (pE-
Ab) peptides [8–10]. This process is catalyzed by the
enzymes glutaminyl cyclase (QC) and iso-glutaminyl
cyclase (isoQC) [9–11]. Both pE-Ab peptides and QC
expression have been found abundantly in both sporadic
and familial AD [7,8,10,12–15], and have been shown to
increase with AD severity [14,16]. The presence of pE in
pE-Ab peptides changes their physicochemical properties,
profoundly increasing their ability to initiate and sustain
self- and co-aggregation with unmodified Ab peptides, lead-
ing to highly toxic Ab-oligomers [17–22]. The seeding
effect of pE-Ab relates to the modified Ab-hypothesis,
where Ab-oligomers are considered the toxic culprit in
AD pathology [23]. New research findings have demon-
strated that pE-Ab/Ab-oligomers appear to be centrally
involved in human AD-like pathology in animal models
and that the pathology and behavioral deficits could be
rescued by means of QC inhibitors [10,24,25]. Thus, the
inhibition of QC in the brain could represent an important
new therapeutic target. PQ912 is a heterocyclic compound
(Fig. 1A) bearing the ability to coordinate QC’s active
zinc-ion [26], while being selective against other metal-
containing enzymes. Its Ki values for human QC and isoQC
enzymes are 29 and 5 nM, respectively. In preclinical
studies, PQ912 showed an attractive drug-like profile (un-
published data) and to investigate this further, the pharmaco-
kinetic (PK) and safety profile of single and multiple PQ912
doses were defined in this phase 1 clinical study.2. Methods
2.1. Study design
This was a randomized, single- and multiple-ascending
oral dose study conducted in two parts. Part 1 comprised a
double-blind, placebo-controlled, ascending single-dose,
sequential-cohort study, incorporating three cohorts with
crossover arms to evaluate a food-effect and formulation-
effect. Part 2 comprised a double-blind, placebo-controlled,
ascending multiple-dose, sequential-cohort study in noneld-
erly and elderly subjects. The study was conducted at Cova-
nce Clinical Research Unit (CRU) in Basel, Switzerland and
Covance CRU in Leeds, UK.
In part 1, subjects were randomized to receive single oral
doses of 10–3600 mg of PQ912 or placebo in each period
(3600 mg was administered as two doses of 1800 mg taken
12hours apart). In part 2, subjects were randomized to
receive twice daily (bid; dose interval of 12 hours) doses,
of 20–800 mg of PQ912 or placebo for 11 days or in case
of 200- and 300-mg dose levels; doses were administeredto elderly subjects for 7 days (see Supplementary Methods
2.1 for further details).2.2. Study subjects
Healthy male and female subjects were enrolled; subjects
were aged between 18 and 55 years in the nonelderly cohorts
and between 65 and 80 years in the elderly cohorts.
The study protocol was approved by institutional re-
view boards for both sites and was conducted in accor-
dance with the Declaration of Helsinki and Good
Clinical Practice guidelines. In addition, the cohorts stud-
ied in Basel were conducted in accordance with Swiss
Federal Laws on Medicinal Products and Medical Devices
(December 2000) and Swiss Regulation on Clinical Trials
with Medicinal Products (October 2001). All subjects
provided written informed consent before participating.2.3. PK and pharmacodynamic assessments
Blood samples were collected for PK and pharmaco-
dynamic (PD) analysis predose and up to 72 hours post-
dose for single-dose cohorts; and predose on day 1, day
7/11, and specified days between days 2 and 7/11, and
up to 96 hours after the last dose for multiple-dose
cohorts.
Cerebrospinal fluid (CSF) samples were collected for PK
and PD analysis from specific dose cohorts (50, 100, and
400 mg single-dose cohorts; 50, 100, and 400 mg nonelderly
multiple-dose cohorts; and 300 and 500 mg elderly multiple-
dose cohorts) at various time points up to 3 hours (50 and
100 mg single-dose cohorts), up to 12 hours (400 mg
single-dose cohort) postdose, and at day -1 and up to 24 hours
after the final dose for multiple-dose cohorts. The rationale
for the CSF sampling scheme after repeated dosing was to
determine (1) maximum CSF concentration (Cmax; the
time to maximum concentration [tmax] was expected be-
tween 2 and 3 hours based on single-dose data), (2) Cmin,
i.e., trough concentration (12 hours after the last dose),
and (3) the concentration 24 hours after dosing for esti-
mating CSF apparent terminal half-life (t1/2). Based on the
PK data acquired during the single-dose study, CSF sam-
pling time points for the multiple-dose cohorts were adjusted
accordingly to assess PQ912. Single-tap lumbar punctures
were performed on each occasion by an anesthetist, and sub-
jects were not sampled more than four times. Samples were
inspected visually before analysis.
Urine samples were collected for PK analysis from all
dose cohorts over various time intervals. For single doses
of 10 to 200 mg of PQ912, urine was collected over a 6-
hour period postdose (day 1), for single doses of 1800 and
3600 mg, urine was collected over a 12-hour period, and
for single doses of 400, 800, and 1200 mg PQ912, urine
was collected over various time intervals up to 48 hours post-
dose. For multiple-dose cohorts of 20–800 mg of PQ912,
Fig. 1. The structural formula of PQ912 and the plasma and CSF concentrations of PQ912 following oral administration. (A) A schematic of the structural form
of PQ912 as a free base. (B) Arithmetic mean concentrations of PQ912 for plasma on day 1 after single oral administration of PQ912 in healthy nonelderly
subjects. (C) Free/protein unbound concentrations of PQ912 in plasma (fub-plasma 5 0.22) and CSF at steady-state (day 11) after multiple bid oral doses
in nonelderly subjects. The lower limit of quantification (dashed line) is 1.00 ng/mL for plasma and 0.1 ng/mL for CSF. Abbreviations: CSF, cerebrospinal fluid;
bid, twice daily (dose interval of 12 hours); fub, free/protein unbound; Soln., solution.
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hour period postdose on day 7/11, as appropriate.
Plasma, urine, and CSF samples were analyzed for
PQ912 and the major metabolite, PQ1345, using a validated
liquid chromatography with tandem mass spectrometric
detection method by Swiss BioQuant, Switzerland (see
Supplementary Methods 2.21 for sample preparation). The
lower and upper limits of quantification for the analysis of
PQ912 and PQ1345 were 1.00–2000 ng/mL for plasma sam-ples, 10–10,000 ng/mL for urine samples, and 0.1–100 ng/
mL for CSF samples. PK parameter estimates for PQ912
and PQ1345 were calculated using standard noncompart-
mental methods of analysis using Phoenix WinNonlin
version 6.2.1 (Pharsight, Mountain View, CA, USA).
PQ1345 results are presented in the Supplementary Data.
The unbound (free) concentrations of PQ912 were estimated
in vitro in human plasma using equilibrium dialysis
(Supplementary Methods 2.2.1.1).
I. Lues et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 182-195 185The QC activity was measured with a coupled assay
using glutaminyl-7-amino-4-methylcoumarin as the sub-
strate and pyroglutamyl aminopeptidase as the auxiliary
enzyme (Probiodrug AG, Germany or Evotec AG, Germany
[27]; Supplementary Methods 2.2.2).
Assessment of the PK/PD relationship was performed on
multiple-dose cohort data. The sigmoidal concentration
response curve was fitted by nonlinear regression according
to the following Emax model: QC activity (% of
baseline) 5 100 ! EC50/(EC50 1 C), where C represents
PQ912 concentration.2.4. Safety assessments
Safety was assessed by physical examinations, clinical
laboratory evaluations, vital signs, electrocardiograms
(ECGs; 12-lead and telemetry), and by monitoring of
treatment-emergent adverse events (TEAEs).2.5. Statistical analysis
No formal statistical assessment of sample size was con-
ducted. However, the number of subjects is common in early
clinical pharmacology studies and was considered sufficient
to achieve the objectives of the study.
See Supplementary Methods 2.5 for further details on the
statistical analyses performed.2.6. Investigational Medicinal Product formulations
Three immediate release formulations of PQ912 were
applied during the study: solution, capsule, and tablets. In
the earlier cohorts when only the noncrystalline free base
of PQ912 was available, initially a reconstituted solution
and later a formulation as a liquid-containing gelatin capsule
(Licaps Technology) were used. With the progression of the
manufacturing process of the active pharmaceutical ingre-
dient and the identification of a crystalline hydrochloride
salt, the development of a solid formulation was accom-
plished and PQ912 hydrochloride was administered as a
film-coated tablet.3. Results
3.1. Demographics and disposition
A total of 206 subjects participated in the study, with
205 subjects completing the study. One hundred and
four subjects aged between 22 and 55 years received sin-
gle doses of PQ912 or placebo, and 102 subjects aged be-
tween 23 and 55 years for the nonelderly dose cohorts and
aged between 65 and 77 years for the elderly dose cohorts
received multiple doses of PQ912 or placebo
(Supplementary Table 1). One subject (500-mg bid,
11 days; capsule, fed) was withdrawn from the study
because of a TEAE of urticaria papular, which startedapproximately 3.5 hours after the 18th dose and was sus-
pected to be related to the study drug.
Overall, 83 subjects were exposed to single doses of up
to 3600 mg of PQ912, and 80 subjects were exposed
to multiple bid doses of up to 800 mg for up to 11 days as
specified.3.2. PK analyses3.2.1. Plasma concentrations of PQ912 after single oral
administration
After single oral solution administration in the fasted
state, PQ912 was rapidly absorbed with mean maximum
plasma concentration (Cmax) attained 0.5 hours postdose
(tmax) for the 10–400 mg doses. At the higher doses of up
to 1800 mg, where formulation was tablet or capsule,
mean tmax was reached approximately 1.0–1.5 hours post-
dose (Fig. 1B and Table 1). After Cmax, plasma concentra-
tions of PQ912 showed a multiexponential decline. The
terminal t1/2 varied between 2–8 hours. However, the half-
life for the concentration decline from tmax to 12 hours post-
dose (t1/2,eff), representing more than 90% of the area under
the concentration versus time curve (AUC), was between 2
and 3 hours and showed less interindividual and across-
the-dose range variation.
The effect of food (tablets: fasted vs. fed) and different
formulations (tablet, fasted vs. capsule, fasted) were investi-
gated at the 200-mg dose level using a crossover design.
Compared to the fasted state, Cmax in the fed state was
52.7% lower and was reached later (least squares mean ratio
of 0.473; 90% confidence intervals [CIs], 0.399–0.559).
However, total systemic exposure to PQ912 (AUC) was
similar between dietary states indicating that the extent of
absorption was not affected by food (least squares mean ratio
of 0.995, 90% CIs, 0.938–1.05; Supplementary Table 2 and
Supplementary Fig. 1).
In addition, tablet (hydrochloride) and capsule (free base)
formulations showed absorption profiles with similar Cmax,
tmax, and AUC (least squares mean ratios [90% CIs] of
0.827 [0.699–0.979] and 0.909 [0.857–0.964] for Cmax and
AUC, respectively; Supplementary Table 2 and
Supplementary Fig. 1). Compared to the solution formula-
tion (Table 1), exposure appeared to be similar, but Cmax
was reached later. However, in view of the number of vari-
ables (different formulations, doses, and age), it cannot be
stated whether the latter was solely due to differences in
formulation.
3.2.2. Dose proportionality and multiple-dose kinetics
Over the 10–200 mg of PQ912 dose range, systemic
exposure of PQ912 increased in a dose-proportional manner,
with the 20-fold dose increment resulting in increases of
approximately 20- and 23-fold for AUC and Cmax, respec-
tively. At higher doses, systemic exposure to PQ912
increased in a supraproportional manner, with a ninefold
Table 1
Summary of plasma pharmacokinetic parameters of PQ912 on day 1 after single doses and on day 7 or 11 after multiple doses
Parameters
Single dose of PQ912 (mg)
10 (n 5 6) 30 (n 5 6) 50 (n 5 6) 100 (n 5 8) 200 (n 5 6) 400 (n 5 12)
800 capsule
(n 5 6)
1200 (fed)
capsule (n 5 6)
1800 tablet
(n 5 6)
AUC0–tlast
(ng.h/mL)
61.0 (38.9) 168 (19.3) 348 (47.0) 685 (31.1) 1343 (21.8) 3542 (49.8) 8546 (20.7) 17,891 (39.8) 32,166 (50.8)
AUC0–12 h
(ng.h/mL)
65.1 (35.3) 171 (17.5) 346 (44.6) 680 (30.5) 1309 (21.0) 3421 (48.6) 8186 (19.8) 16,793 (35.2) 30,525 (48.5)
AUC (ng.h/mL) 66.1 (35.3) 174 (17.8) 355 (46.1) 692 (30.8) 1350 (21.7) 3556 (49.7) 8576 (20.8) 17,914 (39.9) 32,211 (50.8)
Cmax (ng/mL) 36.2 (33.1) 91.4 (17.8) 199 (43.5) 421 (27.0) 818 (19.4) 2152 (31.6) 3444 (36.7) 4714 (16.8) 9676 (31.9)
tmax* (h) 0.500 (0.417–0.517) 0.500 (0.500–0.500) 0.500 (0.500–0.500) 0.500 (0.500–0.533) 0.500 (0.500–0.533) 0.500 (0.333–0.500) 1.50 (0.750–1.50) 1.25 (1.00–3.00) 1.26 (0.500–2.05)
t1/2 (h) 2.11 (22.6) 2.28 (6.4) 2.62 (29.1) 2.47 (14.4) 3.16 (12.4) 3.98 (35.2) 7.77 (85.3) 7.47 (87.5) 5.56 (37.2)
t1/2,eff (h) 2.05 (16.6) 2.30 (7.6) 2.25 (18.0) 2.16 (3.6) 2.43 (10.5) 2.43 (8.8) 2.28 (14.9) 2.45 (25.0) 2.28 (21.3)
CL/f (mL/min) 2520 (35.3) 2872 (17.8) 2349 (46.1) 2407 (30.8) 2469 (21.7) 1875 (49.7) 1555 (20.8) 1116 (39.9) 931 (50.8)
Multiple twice-daily doses (dose interval of 12 h) of PQ912 (mg) for 11 d
Nonelderly healthy subjects Elderly healthy subjects
20 (n 5 8) 50 (n 5 8)
100 (fed)
(n 5 8) 200 (n 5 8)
400 capsule
(n 5 8)
500 (fed)
capsule
(n 5 7)
200y capsule
(n 5 6)
300y capsule
(n 5 8)
500 tablet
(n 5 12)
800 tablet
(n 5 6)
AUC0–12 h
(ng.h/mL)
120 (32.5) 413 (37.3) 969 (26.5) 1833z (35.1) 5946 (16.1) 9302 (63.0) 3891z (35.1) 5658 (48.1) 11,851 (39.4) 24,549 (46.0)
Cmax (ng/mL) 68.4 (36.5) 229 (20.8) 358 (34.6) 1049
z (28.1) 2397 (15.8) 1870 (55.3) 1581z (17.1) 2058 (37.2) 4460 (30.0) 6454 (32.8)
tmax* (h) 0.500
(0.500–0.500)
0.500
(0.500–0.500)
0.750
(0.500–1.50)
0.500 (0.500–0.500) 1.00 (0.500–1.50) 3.00 (1.00–4.05) 1.00 (1.00–1.50) 1.00 (0.500–1.00) 0.500 (0.500–1.00) 1.00 (0.500–1.50)
t1/2 (h) 2.36 (13.9) 2.73 (18.3) 3.46 (16.7) 6.36 (119.7) 5.74 (63.2) 6.82 (61.9) 7.55 (93.3) 6.28 (37.4) 7.58 (24.7) 7.67 (30.0)
t1/2,eff (h) 2.46 (23.2) 2.62 (10.2) 2.44 (7.8) 2.72 (11.6) 2.49 (15.4) 3.01 (28.6) 3.08 (18.6) 2.85 (21.2) 2.78 (15.9) 3.22 (17.9)
CL/f
(mL/min)
2778 (32.5) 2018 (37.3) 1721 (26.5) 1818 (35.1) 1121 (16.1) 896 (63.0) 857 (35.1) 884 (48.1) 703 (39.4) 543 (46.0)
Day 7/11:
day 1 ratio
1.15 (9.8) 1.10 (12.8) 1.13 (9.0) 1.19 (16.6) 1.30 (19.4) 1.71 (36.0) 1.21 (11.1) 1.34 (16.6) 1.30 (17.4) 1.57 (19.9)
Abbreviations: n, number of subjects; AUC0–tlast, area under the concentration versus time curve from time 0 h to the last data point tlast after drug administration above the limit of quantitation on day 1;
AUC0–12h 5 area under the concentration versus time curve from time 0 h to the available and quantifiable sampling point closest to 12 h after dosing; AUC, area under the concentration versus time curve
extrapolated to infinity; Cmax, maximum observed concentration; tmax, time to reach maximum concentration; t1/2, apparent terminal half-life; t1/2,eff, apparent half-life in the range of 2–12 h postdose; CL/f,
total body clearance; CV, coefficient of variation.
NOTE. All data presented are for doses administered as solutions under fasted conditions unless stated otherwise. Geometric mean (CV%) data are presented.
*Median (min–max).
yDoses administered for 7 d for these cohorts.
zThe ratios and 90% confidence intervals for the geometric least squares means of elderly: nonelderly subjects are 2.02 (1.43–2.85) and 1.72 (1.31–2.26) for day 1, and 2.12 (1.51–2.99) and 1.51 (1.15–1.98) for
day 7/11, for AUC0–12 h and Cmax, respectively.
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crease in AUC (Table 1).
After bid doses of PQ912, the disposition of PQ912 in
plasma was similar to that after single dosing, with a multi-
exponential decline after Cmax, and t1/2,eff values of approx-
imately 2–3 hours (Table 1). Visual examination of the
morning trough PQ912 concentrations for individual sub-
jects showed steady-state was achieved within 2 days after
start of the multiple bid dosing. After repeated dosing up
to 400 mg, accumulation (AUC from time 0–12 hours after
dosing [AUC0–12 h] day 11/day 1 ratio) of PQ912 was min-
imal. In addition, systemic exposure to PQ912 on day 11
appeared to increase in a supraproportional manner from
20 to 200 mg, with the 10-fold dose increment resulting
in increases of approximately 15-fold for AUC0–12 h and
Cmax (Table 1).
Healthy elderly subjects were also administered multiple
bid doses of PQ912, demonstrating a similar t1/2,eff to non-
elderly subjects. Analysis showed a statistically significant
1.5- to 2.1-fold increase in AUC0–12 h and Cmax values of
elderly subjects (capsule) compared with nonelderly sub-
jects (solution) on day 1 and day 7/11 at the 200-mg dose
(Table 1). However, because of the different PQ912 formu-
lations administered at this dose, it cannot be excluded that
differences in formulation contributed to the observed
increase in exposure.
3.2.3. Comparison of PQ912 concentrations in CSF and
plasma
After single oral solution administration, the highest con-
centrations of PQ912 in the CSF were observed after 3 hours
(CSF sampling times: 1, 1.5, and 3 hours; data not shown). In
addition, concentrations after repeated dosing (CSF sam-
pling times: 2, 3, 6, 12, and 24 hours after final dose on
day 7/11) indicated that peak CSF concentrations were
reached at between 2 and 3 hours (Supplementary Fig. 2
and Supplementary Table 3). Thus, Cmax in the CSF was
reached considerably later than in plasma (tmax: 0.5–1 hours;
Table 1). In contrast to plasma, concentrations in CSF
showed a monoexponential decline (Fig. 1C), with a t1/2 be-
tween 6 and 7 hours (Table 2). This was similar to the termi-
nal plasma t1/2 (doses 200-mg bid), but much longer than
the t1/2,eff of 2–3 hours in plasma (Fig. 1B and Table 1).
Thus, after repeated bid dosing (50 mg), trough values
(12 hours postdose) in plasma were up to 61-fold lower
than peak levels, but only approximately threefold lower in
CSF (plasma trough values for the 20-mg bid group were
generally below the limit of quantification).
Concentrations of PQ912 in CSF were lower than those in
plasma, with the AUC approximately 4%–5% of the plasma
AUC for total PQ912 (Table 2) and about 20% when
compared with the AUC of the unbound fraction of PQ912
(0.22).
The CSF/plasma AUC ratios were found to be indepen-
dent of dose, and when compared with the AUCs, these ra-
tios showed only small interindividual differences
I. Lues et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 182-195188(Table 2). Thus, if unknown, the AUC in CSF can be esti-
mated from plasma AUC with reasonable accuracy.
It should be noted that the number of CSF samples per
subject was limited; thus, calculation of AUC was based
on three time points only (3, 12, and 24 hours postdose;
Fig. 1C and Table 2). For simplicity, it was assumed that
the 3-hour value represented the maximum concentration;
however, concentrations of samples taken at earlier time
points in single-dose groups suggested that maximum
levels were reached earlier, between 2 and 3 hours. Because
of this, the value for the AUC in CSF was considered as a
low estimate, with its “true” value likely to be 10%–15%
higher (Table 2).3.3. QC activity in serum and CSF at predose and after
PQ912 administration
To study the effect of PQ912 on the target enzyme, QC,
its activity was determined in serum and CSF.
The mean baseline serum QC activity in elderly subjects
was approximately 12% higher than in nonelderly subjects
(Fig. 2A; unpaired t test, P 5 .0012). Although this differ-
ence suggests a slight increase of QC activity with age, in
view of the much larger interindividual differences
(Fig. 2B), no definite statement can be made in this respect.
Day-to-day variation in QC activity was minor i.e., pre-
morning dose activities in subjects receiving placebo
differed on average less than 10% over the study period of
11 days (Fig. 2C). Minor within-day differences were
observed, with the activity at 8 hours after first dose onFig. 2. Serum and CSF QC activity profiles. (A) Serum and CSF QC activity at base
at baseline and subject age. (C) Daily mean serum QC activity premorning dose of
1 and day 11 for subjects who received placebo bid for 7 of 11 days. Abbreviation
ation; bid, twice daily (dose interval of 12 hours).day 1 and day 11 on average 13% lower (P , .01) than the
respective predose value (Fig. 2D).
The mean baseline activity of QC in CSF was
376 mU/L and, thus, similar to that observed in serum
with a CSF/serum ratio of 0.94 (n 5 30; 95% CI, 0.84–
1.03; Fig. 2A).
After single and multiple doses of PQ912, QC activity in
serum and CSF decreased in a dose-related manner (Fig. 3).
For an estimate of half maximal effective concentration
(EC50) in serum and CSF, changes in QC activity were
plotted versus PQ912 concentrations and fitted to an Emax
model (Fig. 4A and B, respectively). This model provided
a good description of the data, with the exception of a cluster
of serum data points at low PQ912 concentrations that
showed higher than predicted inhibition. We believe that
this may be due to diurnal fluctuations of QC activity, which
were also observed in placebo-treated subjects where QC ac-
tivity was approximately 13% lower at 6 and 8 hours
compared with predose values (Fig. 2D). For low inhibitor
concentrations (low doses and late time points), this would,
therefore, result in the observed stronger decrease in QC ac-
tivity. This model provided EC50 values of 14 and 11 ng/mL
(42 and 32 nM, respectively) for serum and CSF, respec-
tively, and thus was in good agreement with the Ki value
of 29 nM determined in vitro, in matrix-free solutions.
Thedata collectedwithin this studywere used to establish a
simple relationship between plasmaAUCandCSF concentra-
tion, with the plasma AUC used to estimate the likely target
inhibition in CSF (Table 2). The assumptions for this model
were as follows: (1) The AUC in CSF is 5% of that in plasma.line in elderly and nonelderly subjects. (B) Scatter plot of serumQC activity
subjects who received placebo bid for 11 days. (D) SerumQC activity on day
s: CSF, cerebrospinal fluid; QC, glutaminyl cyclase; CV, coefficient of vari-
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of 4.6% derived from experimental data, but for reasons out-
lined in Section 3.2.3, this is believed to be justified; (2) CSF
concentrations declined in a monoexponential fashion with a
t1/2 of approximately 6 hours. From this it can be derived that
CSF concentrations after 3 and 12 hours are approximately
1.6- and 0.53-fold the mean concentration, respectively; (3)
QC inhibition byPQ912was assumed to follow a simple bind-
ing model using a Ki of 29 nM determined in vitro. This Ki
value was in good agreement with the experimental EC50
value of 32 nM (Fig. 4B).
Thus, we believe that concentrations of PQ912 and the
target inhibition in CSF can be estimated with reasonable
accuracy from the plasma AUC without the need of CSF
sampling. According to the estimates presented in
Table 2, the mean target inhibition varied from 5% to
91%, across the dose range. As predicted by the binding
model, the within-dose interval target inhibition varied at
low doses by almost a factor of 3 (similar to CSF concen-
trations), but at 800 mg, only between 85% and 94%. In
contrast, the variation in plasma was much larger with
steady-state PQ912 peak levels being up to 61-fold
higher than that of trough concentrations.3.4. Safety and tolerability
There were no apparent trends in the number of subjects
reporting TEAEs across the doses of PQ912 administered
(Table 3). After single doses of PQ912, the incidence of
drug-related TEAEs was low with 25 events reported by
16 of 104 subjects, and after multiple doses, 113 drug-
related TEAEs were reported by 47 of 102 subjects.
Most TEAEs reported after PQ912 administration
were mild or moderate in severity and resolved without treat-
ment and there were no serious adverse events reported dur-
ing the study. Three severe adverse events were reported;
two events of presyncope (placebo solution, fasted and
100-mg bid solution, fed; neither were considered to be
related to study drug) and an event of pyrexia (500-mg bid
solution, fed). The event of pyrexia was reported by the sub-
ject whowas withdrawn from the study due to a TEAE of ur-
ticaria papular (Section 3.1).
The most frequently reported type of TEAE across all
dose cohorts were gastrointestinal disorders. The incidence
remained similar across all nonelderly dose cohorts, but at
the two highest dose levels in elderly subjects incidence
was slightly higher. In addition, the most frequently reported
individual TEAE was headache, although the incidence was
not dose dependent (Table 3).
There were no safety concerns for any of the clinical lab-
oratory parameters assessed; although, four subjects experi-
enced changes in clinical laboratory parameters, which were
considered to be clinically significant, with increases
observed in serum potassium (one subject; 50-mg solution,
fed), erythrocytes (one subject; 500-mg bid capsule fed),and leukocytes (two subjects; 200-mg bid capsule, fasted,
elderly and 500-mg bid capsule, fed).
There were no clinically significant findings in the safety
assessments of vital signs, 12-lead ECGs, telemetry, or phys-
ical examinations during the study.4. Discussion
PQ912 is a first-in-class compound addressing the novel
target QC, which appears to be very relevant in the Ab pa-
thology of AD [10]. This present study was a first-in-man
single- and multiple-ascending oral dose study, which as-
sessed the safety, PK, and PD of PQ912.
Eighty-three subjects were exposed to single doses of
PQ912 up to 3600 mg (within a period), and 80 subjects
were exposed to multiple bid doses of PQ912 up to
800 mg. Overall, PQ912 was considered to be safe and
well tolerated across all doses, with most adverse events
mild or moderate in severity. The most frequently re-
ported group of TEAEs were classified as gastrointestinal
disorders, and the most frequently reported TEAE was
headache. No correlations were noted between the fre-
quency and severity of TEAEs and the dose level, age,
sex, or dietary state, except at the higher doses (500-
and 800-mg bid) where a slightly higher incidence of
gastrointestinal TEAEs was reported in elderly subjects.
The reason for this is not known at present; however,
the higher number of tablets taken, the higher systemic
or local concentration of the drug, and/or the total mass
of the drug released in the gastrointestinal tract may
have contributed to this observation.
In addition to being safe and well tolerated, this study has
demonstrated that oral administration of various formula-
tions provides dose-proportional or supraproportional expo-
sure of PQ912 in both plasma and CSF. At the 200-mg dose,
an increase in exposure was also apparent in the elderly
compared with the nonelderly population. Although differ-
ences in formulation may have contributed to this increase,
it could indicate a decrease in clearance with age, possibly
due to a reduced liver blood flow in elderly or due to an
age-related decrease in the capacity to metabolize this
drug. Overall, absorption was rapid, with tmax observed
generally 0.5–1.5 hours postdose. The t1/2,eff of PQ912 in
plasma was 2–3 hours, but approximately 6 hours for CSF
(t1/2). Thus, after repeated dosing, trough concentrations
were up to 61-fold lower than peak levels in plasma and
approximately threefold lower in CSF. The finding that
AUC in CSF was only approximately 20% of the AUC in
plasma for unbound PQ912 suggested some active efflux,
which according to in vitro studies could have been P-glyco-
protein mediated (unpublished data).
Due to the longer t1/2 in the clinically relevant CSF
compartment, a relatively constant target inhibition of QC
can be achieved at the higher bid doses. The CSF QC target
inhibition was estimated to be approximately 70% after bid
dosing of 400 mg in nonelderly subjects, and 90% at 800-mg
Fig. 3. Arithmetic mean percentage changes from baseline in serum QC activity after single oral doses of PQ912 in healthy nonelderly subjects. Abbreviations:
QC, glutaminyl cyclase; Soln., solution.
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interval fluctuations.
Information on in vivo QC activity in plasma and CSF
is limited, with Gontsarova et al. [28] being the first to
publish evidence of QC activity in human CSF. To our
knowledge, the present study was the first to quantify
QC activity in human plasma and CSF. The QC activity
profile showed minimal change with age and no or little
within-day or day-to-day fluctuations. This is an impor-
tant preparatory data set for further evaluating QC activity
in AD patients, as currently only QC messenger RNA
(mRNA) expression and protein levels have been shown
to be increased in the blood and brain of early AD patients
[14,16,29]. In these studies, levels of QC mRNA and
protein levels correlate with an accumulation of pE-Ab
in human brains and with cognitive decline, and thus, in
future patient studies we will further evaluate QC
activity in plasma and CSF and pE-Ab levels in CSF to
learn about their potential as stratification and/or
therapeutic biomarkers.Fig. 4. The pharmacokinetic/pharmacodynamic relationship between PQ912 conc
plasma concentrations versus serum QC inhibition. (B) Correlation of PQ912 CSF
fluid; QC, glutaminyl cyclase.The potential of QC inhibition for the treatment of AD and
thus, the potential of PQ912, has been demonstrated by a num-
ber of preclinical studies. UsingADmousemodels, the potent
cytotoxicity of pE-Ab peptides and the potential role that
these peptides play in the initial stages of AD pathology
have been demonstrated [30]. In addition, other recent studies
have demonstrated the effect of QC inhibition in reducing pE-
Ab peptides and total Ab levels in similar ADmouse models,
with long-term administration resulting in decreased soluble
pE-Ab and plaque density in the brain and significantly
improved memory and cognition [10,14,25].
To develop an active central nervous system drug for
treatment of chronic diseases such as AD, characterization
of its brain penetration and target inhibition combined
with its safety and tolerability is important for further clin-
ical development. Therefore, emphasis was placed on esti-
mating target engagement by means of a PK/PD
correlation in CSF, as a measure of brain exposure [31].
Overall, the study established a PK/PD correlation be-
tween plasma and CSF, which allows estimation of the targetentration and QC inhibition in serum and CSF. (A) Correlation of PQ912 free
concentration versus CSF QC inhibition. Abbreviations: CSF, cerebrospinal
Table 3
Treatment-emergent adverse events after single and multiple oral administration of PQ912
Single dose of PQ912 or placebo (mg)
Pooled placebo
(n 5 21)
10 solution
(n 5 6)
30 solution
(n 5 6)
50 solution
(n 5 6)
100 solution
(n 5 8)
200 solution
(n 5 6)
400 solution
(n 5 12)
800 capsule
(n 5 6)
1200 (fed)
capsule (n 5 6)
1800 tablet
(n 5 6)
3600* tablet
(n 5 6)
Subjects with AEs 8 (38.1) — 2 (33.3) 5 (83.3) 3 (37.5) — 4 (33.3) 1 (16.7) 1 (16.7) 2 (33.3) —
Number of AEs 12 — 2 11 7 — 7 2 2 2 —
Most frequent TEAEs (2 subjects)
Nausea — — — 1 [1] — — — 1 [1] — 2 [2] —
Vomiting — — — 1 [2] — — — 1 [1] — — —
Headache 4 [5] — — 2 [3] — — 1 [1] — 1 [1] — —
Back pain — — 1 [1] 1 [1] 3 [3] — 2 [2] — — — —
Fatigue — — — 1 [1] 1 [1] — — — — — —
Presyncope 1 [1] — — — — — 1 [1] — — — —
Injection site pain — — — 1 [1] — — 1 [1] — — — —
Nasopharyngitis 2 [2] — — — — — — — — — —
Multiple twice-daily doses (dose interval of 12 h) of PQ912 or placebo (mg)
Nonelderly healthy subjects Elderly healthy subjects
Pooled placebo
(n 5 12)
20 solution
(n 5 8)
50 solution
(n 5 8)
100 (fed)
solution (n 5 8)
200 solution
(n 5 8)
400 capsule
(n 5 8)
500 (fed)
capsule (n 5 8)
Pooled placebo
(n 5 10)
200y capsule
(n 5 6)
300y capsule
(n 5 8)
500 tablet
(n 5 12)
800 tablet
(n 5 6)
Subjects with AEs 6 (50.0) 7 (87.5) 7 (87.5) 8 (100.0) 6 (75.0) 5 (62.5) 8 (100.0) 6 (60.0) 3 (50.0) 6 (75.0) 9 (75.0) 6 (100)
Number of AEs 19 16 22 16 11 9 30z 11 3 13 32 34
Most frequent TEAEs (3 subjects)
Nausea 1 [1] — 1 [1] — 1 [1] — 1 [1] — — — 3 [4] 2 [2]
Flatulence 1 [1] — — — 1 [1] — — 1 [1] — — — 3 [3]
Constipation — — — — — — — 1 [1] — — 2 [2] 2 [2]
Abdominal pain — 1 [1] 1 [1] — 1 [1] 1 [1] 1 [1] — — — 1 [1] —
Diarrhea — — — — 1 [1] — 1 [1] — — — 1 [1] 1 [1]
Headache 3 [4] 3 [7] 4 [8] 3 [4] — 3 [4] 3 [3] 1 [1] — 4 [4] 2 [4] 2 [2]
Back pain 1 [1] — — 1 [1] 1 [1] 1 [1] 4 [5] 2 [2] — 1 [1] 1 [1] —
Pain in extremity 1 [1] — — — — — 2 [2] — — 1 [2] — —
Neck pain 1 [1] 1 [1] — — 1 [1] — — — — — — 1 [1]
Abnormal sensation
in eye
1 [1] — — — — — 2 [2] — — — — —
Pollakiuria — — — — — — — 1 [1] — — — 2 [2]
Presyncope — — — 6 [6] — 1 [1] — — — — — —
Dizziness 1 [1] — 1 [1] — — — 2 [2] — — — 1 [2] —
Injection site pain — — 5 [6] 3 [3] — — — 2 [2] — 4 [4] 1 [1] —
Chest pain — — 1 [1] 1 [1] 1 [1] — — — — — — 1 [2]
Contusion — — — — — — — — — — 2 [3] 1 [1]
Abbreviations: n, number of subjects; AEs, adverse events; TEAEs, treatment-emergent adverse events.
NOTE. Pooled placebo includes all placebo subjects for the dose cohorts presented. All active doses are fasted unless stated otherwise. Values in [ ] refer to the number of TEAEs, and values in ( ) refer to the
percentage of total subjects.
*Administered as two doses of 1800 mg 12 h apart.
yDosed for 7 d.
zOne subject was discontinued from the study because of a TEAE.
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I. Lues et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 182-195192inhibition in CSF from plasmaAUCwithout the need for CSF
sampling. The results of this study suggest that clinical doses
that provide 70%–90% QC inhibition are well tolerated and,
therefore, justify the further evaluation of PQ912 in patients.
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1. Systematic review: The authors reviewed relevant
literature using traditional sources and meeting ab-
stracts/presentations, which are cited appropriately.
2. Interpretation: This was the first time that a com-
pound targeting glutaminyl cyclase (QC) enzyme
inhibition had been assessed in a clinical setting
for the inhibition of pyroglutamate-amyloid-b (pE-
Ab) formation and, thus, potentially the treatment
of Alzheimer’s disease (AD). Our results show
that PQ912 was safe and well tolerated in healthy
nonelderly and elderly subjects, and that it had
dose-dependent inhibition of QC in blood and
cerebrospinal fluid (CSF).
3. Future directions: A major objective of a phase 2
study will be to evaluate the safety of PQ912 in the
patient population and to explore the hypotheses
that inhibition of QC interferes with Ab pathology
and leads to cognitive improvement. In addition,
we will further evaluate QC activity and pE-Ab
levels in CSF to learn about their potential as AD bio-
markers and how PQ912 can be of benefit in modi-
fying these molecules.References
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Supplementary Fig.1. Arithmetic mean plasma concentrations of PQ912 following single oral doses of tablet and capsule formulations of PQ912 in healthy
subjects under fed and fasted conditions. Lower limit of quantification (- - -) was 1.00 ng/mL.
Supplementary Fig.2. Arithmetic mean CSF concentrations of PQ912 following multiple oral doses of PQ912 in healthy subjects. Lower limit of quantification
(- - -) was 0.1 ng/mL. Abbreviations: bid 5 twice daily (dose interval of 12 h); Soln. 5 solution.
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Supplementary Fig.3. Arithmetic mean plasma concentrations of PQ1345 on Day 1 following single oral administration of PQ912. Lower limit of quantification
(- - -) was 1.00 ng/mL. Abbreviations: Soln. 5 solution.
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